Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab, ixekizumab, and bimekizumab, and the anti-17RA monoclonal antibody brodalumab, are approved for some immune-mediated inflammatory diseases, such as psoriasis (82–84), psoriatic arthritis (85, 86), and ankylosing spondylitis (87, 88). Here, IL17A is linked to psoriatic arthritis.